FDA
-
-
-
-
-
-
-
BridgeBio Raises $1 Billion in Preferred Equity to Accelerate Present and Upcoming Launches
-
-
-
-
-
-
-
BridgeBio submits FDA application for rare disease drug encaleret
-
-
-
-
-
-
-
BridgeBio to Present New Acoramidis Data on Disease Progression, Biomarkers, and Clinical Outcomes at ESC-Heart Failure 2026
-
-
-
-
-
-
-
Leerink Partners Reiterates Outperform Rating on BridgeBio Pharma (BBIO) after data presentation: "risk/reward skewed to the upside"
-
-
-
-
-
-
-
BridgeBio reports $362.4 million in Attruby revenue for 2025
-
-
-
-
-
-
-
BridgeBio Reports Third Quarter 2025 Financial Results and Business Updates
-
-
-
-
-
-
-
Acoramidis Begins to Reduce Cumulative Cardiovascular Outcomes Within the First Month of Treatment in Patients with ATTR-CM
-
326,426 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

